Cited by 843Lung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis

Open access

Lee, Chee Khoon, Man, Johnathan, Lord, Sally, Links, Matthew, Gebski, Val, Mok, Tony, Yang, James Chih-Hsin·2017·Journal of Thoracic Oncology

DOI 10.1016/j.jtho.2016.10.007

Open this paper in CoChat — free account Open PDF

Abstract

Introduction We performed a meta-analysis to assess the role of immune checkpoint inhibitors as second-line therapy in EGFR-mutant advanced NSCLC.Methods Randomized trials comparing immune checkpoint inhibitors against chemotherapy were identified. We retrieved the hazard ratio (HR) and 95% confidence interval (CI) for overall survival (OS) of the intention-to-treat population and EGFR mutation-defined subgroups. We used the fixed-effects inverse variance-weighted method to pool estimates of treatment efficacy. Statistical tests were two sided.Results In the three included studies that compared immune checkpoint inhibitors (nivolumab [n = 292], pembrolizumab [n = 691], and atezolizumab [n =144]) against docetaxel (n = 776), immune checkpoint inhibitors significantly prolonged OS over that with docetaxel overall (n = 1903, HR = 0.68, 95% CI: 0.61-0.77, p < 0.0001) and in the EGFR wild-type subgroup (n = 1362, HR = 0.66, 95% CI: 0.58-0.76, p < 0.0001) but not in the EGFR-mutant subgroup (n = 186, HR = 1.05, 95% CI: 0.70-1.55, p < 0.81; treatment-mutation interaction p = 0.03).Conclusion In EGFR-mutant advanced NSCLC, immune checkpoint inhibitors do not improve OS over that with docetaxel. Mechanisms of acquired resistance to first-line tyrosine kinase inhibitor therapy should be elucidated to guide selection of second-line treatment for these patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2016.10.007

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
Self-citation
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Gainor, J. F., Shaw, A. T., Sequist, L. V. D., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L. E., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,268
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,250
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
Takezawa, K., Pirazzoli, V., Arcila, M. E., Nebhan, C. A., Song, X., de Stanchina, E., Ohashi, K., Janjigian, Y. Y., Spitzler, P. J., Melnick, M. A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0108 · Cited by 710

Show all 15 references

Sorted by citations

Items 601–700 of 843

Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer
Zhang, X., Zhang, H., Hou, F., Fang, T., Zhang, C., Wang, H., Song, S., Lan, H., Wang, Y., & Hou, H. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03434-1 · Cited by 4
EGFR-TKI combination treatment for NSCLC with EGFR-sensitive mutation
Wu, Y., Yh, L., Onzere, L. E., Quan, W., Zhang, X., & Ma, J. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2520962 · Cited by 6
Patient with Three EGFR Mutations – Gradual Development of Resistance to Previous Targeted Treatment
Svatoň, M., Pešek, M., Baxa, J., Mukenšnábl, P., Benešová, L., & Minárik, M. (2018) · Klinicka onkologie · doi:10.14735/amko201853 · Cited by 4
Are Immune Checkpoint Inhibitors Effective Against Uncommon Oncogene-Driven NSCLC Subtypes?
Eguren‐Santamaría, I., Sanmamed, M. F., & Bazo, I. G. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.02.003 · Cited by 4
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review
Leone, G., Passiglia, F., Bironzo, P., Bertaglia, V., & Novello, S. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-710 · Cited by 4
Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study
Zhao, S., Zhang, Z., Fang, W., Zhang, Y., Zhang, Z., Hong, S., Ma, Y., Zhou, T., Yang, Y., Huang, Y., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.587849 · Cited by 5
Pembrolizumab and chemotherapy in non‐small cell lung cancer with EGFR ex20ins mutation: A case report
Zhang, M., Nie, L., & Cheng, Y. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14101 · Cited by 4
Dramatic response to osimertinib combined with crizotinib in EGFR T790 M mutation only in blood and Met amplification only in tumor tissue expressive non-small cell lung cancer
Li, D., Gui, Q., Xu, C., Shen, M., & Chen, K. (2021) · Medicine · doi:10.1097/md.0000000000026375 · Cited by 4
Case Report: An “Immune-Cold” EGFR Mutant NSCLC With Strong PD-L1 Expression Shows Resistance to Chemo-Immunotherapy
Zhao, Q., Zhang, X., Ma, Q., Luo, N., Liu, Z., Wang, R., He, Y., & Li, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.765997 · Cited by 4
Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting
Kraskowski, O., Stratmann, J., Wiesweg, M., Eberhardt, W., Metzenmacher, M., Schmid, K. W., Herold, T., Schildhaus, H., Darwiche, K., Aigner, C., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04839-3 · Cited by 5
For a better adjuvant strategy for resected lung cancer—lessons from treatment failure patterns of the ADJUVANT trial (CTONG 1104)
Suda, K. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.08.24 · Cited by 4
Unearthing EGFR Mutations and the Rewards of Persistence in Precision Oncology: Breaching the 10-Year Survival Barrier in Metastatic NSCLC With Active Disease
Singh, P. K., Kumar, R., Bal, A., Gupta, N., Kapoor, R. K., Prasad, K. T., & Singh, N. (2020) · JCO Global Oncology · doi:10.1200/jgo.19.00357 · Cited by 4
The emerging development of tumor mutational burden in patients with NSCLC
Zhang, Y., Wang, L., Li, R., & Liu, B. (2020) · Future Oncology · doi:10.2217/fon-2019-0650 · Cited by 4
Response with pembrolizumab in a patient with EGFR mutated non-small cell lung cancer harbouring insertion mutations in V834L and L858R
Hadfield, M. J., Turshudzhyan, A., Shalaby, K., & Reddy, A. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211057867 · Cited by 4
Folic acid-mediated MSNs@Ag@Geb multifunctional nanocomposite heterogeneous platform for combined therapy of non-small cell lung cancer
Lin, J., Zheng, R., Huang, L., Tu, Y., Li, X., & Chen, J. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112639 · Cited by 4
Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents
Puri, S., Chatwal, M. S., & Gray, J. E. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1361323 · Cited by 4
Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer
Gainor, J. F. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.23 · Cited by 4
Immunotherapy supplanting chemotherapy for upfront treatment of advanced non-small cell lung cancer: what’s next?
Ilié, M., & Hofman, P. M. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.03.155 · Cited by 4
Impact of PD-L1 Expression in EGFR-Positive NSCLC? The Answer Remains the Same…
Heigener, D. F., & Reck, M. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.001 · Cited by 4
PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Addeo, A., & Banna, G. L. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.07.09 · Cited by 4
Lymphocyte subset-based non-invasive biomarker predicts immunochemotherapy efficacy in EGFR-TKI-pretreated EGFR-mutated NSCLC
Song, L., Zeng, L., Xu, Q., Li, Y., Guo, W., Lin, S., Jiang, W., Wang, Z., Deng, L., Huang, Z. H., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113211 · Cited by 3
Perioperative Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Otis, S. U., Banna, G. L., & Maniam, A. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01720-z · Cited by 4
Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC – Insights From Genomics, Proteomics, and Metabolomics
Elayeh, E. R., Aleidi, S., Aboud, O., Semreen, M., Bustanji, Y., & Dahabiyeh, L. (2025) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s539777 · Cited by 3
Durvalumab plus etoposide–platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD
Okamoto, I., Cho, B. C., Goldberg, S. B., Goldman, J. W., de Langen, A. J., Piotrowska, Z., Riess, J. W., Yu, H. A., Campelo, M. R. G., Cetnar, J. P., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109501 · Cited by 3
Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non–Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked
Bodor, J. N., Patel, J. D., Wakelee, H. A., Levy, B. P., Borghaei, H., Pellini, B., Costello, M. R., Dowell, J. E., Finley, G. G., Huang, C. H., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.05.003 · Cited by 3
Molecular testing in non-small cell lung cancer: A consensus recommendation
Lai, G. G. Y., Cheng, X. M., Ang, Y. L. E., Chua, K. L. M., Samol, J., Soo, R. A., Tan, D. S. W., Lim, T. K. H., & Lim, W. (2023) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2022473 · Cited by 3
The Association Between Modified Albumin-Bilirubin (mALBI) and Survival in Advanced Non-small Cell Lung Cancer Patients Treated With Immunotherapy
Xu, X., Shi, X., Zhou, D., & Cao, D. (2024) · Cureus · doi:10.7759/cureus.56074 · Cited by 3
Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer
Huber, R. M., & Kauffmann-Guerrero, D. E. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001110 · Cited by 3
Exploring the Expression of CD73 in Lung Adenocarcinoma with EGFR Genomic Alterations
Long-Mira, É., Bontoux, C., Rignol, G., Hofman, V., Lassalle, S., Benzaquen, J., Boutros, J., Lalvée, S., Zahaf, K., Lespinet‐Fabre, V., et al. (2025) · Cancers · doi:10.3390/cancers17061034 · Cited by 3
Trends in Overall Survival in Lung Adenocarcinoma with EGFR Mutation, KRAS Mutation, or No Mutation
Faehling, M., Fallscheer, S., Schwenk, B., Seifarth, H., Sträter, J., Lengerke, C., & Christopoulos, P. (2025) · Cancers · doi:10.3390/cancers17071237 · Cited by 3
Identification of a Gene Signature Closely Related to Immunosuppressive Tumour Microenvironment Predicting Prognosis of Patients in EGFR Mutant Lung Adenocarcinoma
Li, J., Li, H., Zhang, C., Zhang, C., Jiang, L., Wang, H., & Liu, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.732841 · Cited by 3
Role of immunotherapy in metastatic EGFRm NSCLC
Dhabhar, B. N., Sahoo, T. P., & Akshay, J. K. (2022) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_49_21 · Cited by 3
The efficacy of adding hyperthermia to the treatment of advanced NSCLC patients based on the states of EGFR
Zhou, Y., Zhong, Q., Huang, D., Li, Q., Huang, J. H., Wang, C., Chen, B., Chen, M., Li, Y., & Liu, W. (2022) · Aging · doi:10.18632/aging.204148 · Cited by 3
Genomic Mapping of Epidermal Growth Factor Receptor and Mesenchymal–Epithelial Transition-Up-Regulated Tumors Identifies Novel Therapeutic Opportunities
Paniagua‐Herranz, L., Doger, B., Díaz‐Tejeiro, C., Sanvicente, A., Nieto‐Jiménez, C., Moreno, V., Pérez‐Segura, P., Győrffy, B., Calvo, E., & Ocaña, A. (2023) · Cancers · doi:10.3390/cancers15123250 · Cited by 3
Localization ofEGFRMutations in Non-small-cell Lung Cancer Tissues Using Mutation-specific PNA-DNA Probes
Shigeto, H., Miyata, H., Ashizawa, T., Iizuka, A., Kikuchi, Y., HOZUMI, C., Maeda, C., Yamaguchi, K. D., Yamamura, S., & Akiyama, Y. (2023) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20389 · Cited by 3
Treatment Patterns and Adverse Event-Related Hospitalization Among Patients with Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non-small Cell Lung Cancer After Treatment with EGFR Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy Regimens
Marrett, E., Kwong, W. J., Xie, J., Manceur, A. M., Sendhil, S. R., Wu, E. Q., Ionescu‐Ittu, R., & Subramanian, J. (2023) · Drugs - Real World Outcomes · doi:10.1007/s40801-023-00383-1 · Cited by 3
Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations
Shang, X., Zhang, W., Han, W., Xia, H., Liu, G., Wang, X., & Liu, Y. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02707-x · Cited by 3
EGFR amplification indicated poor prognosis in EGFR‐mutated lung cancer with leptomeningeal metastases
Geng, D., Niu, R., Li, J., Guo, S., Guo, Q., Huang, S., Wang, Y., & Li, X. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.13733 · Cited by 3
Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study
Riess, J. W., Lara, M. S., de Rodas, M. L., Luxardi, G., Herbert, S. M., Shimoda, M., Kelly, K. L., Meerlev, A., Moore, E., Beckett, L. A., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100706 · Cited by 3
EGFR-TKIs Combined with Allogeneic CD8+ NKT Cell Immunotherapy to Treat Patients with Advanced EGFR-Mutated Lung Cancer
Ye, F., Yuan, X., Yu, W., Ma, Y., Mao, C., Li, X., Li, J., Dai, C., Qian, F.-H., Li, J., et al. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241273198 · Cited by 3
Are lung adenocarcinoma mutations shaping the immune microenvironment?
Rochigneux, P., & Garon, E. B. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.07.17 · Cited by 3
Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR‐mutant and EGFR‐wild type nonsquamous non‐small cell lung cancer
Huang, Y., Shen, S., Liu, C., Pavlidis, S. P., Wang, C., Ko, H., Chung, F., Lin, T., Feng, P., Lee, K., et al. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12875 · Cited by 3
Efficacy and safety of pembrolizumab monotherapy in EGFR-mutant squamous cell lung cancer with PD-L1 over-expression: A case report
Liu, Q., Wei, J.-G., Chen, Y., & Wang, J. (2022) · Medicine · doi:10.1097/md.0000000000030099 · Cited by 3
Neoadjuvant Immunotherapy Plus Chemotherapy and Adjuvant Targeted Therapy in ALK -Positive Non-Small-Cell Lung Cancer
Song, Q., Li, J., Xiong, Q., Long, Y., Yang, B. Y., Dong, Z. H., Liang, C. Y., & Yang, B. Y. (2023) · Immunotherapy · doi:10.2217/imt-2022-0302 · Cited by 3
Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression
Uenami, T., Ishijima, M., Kanazu, M., Kurebe, H., Edahiro, R., Nishida, K., Akazawa, Y., Yano, Y., Yamaguchi, T., & Mori, M. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.10.24 · Cited by 3
Commemorating the 20th anniversary of the discovery of epidermal growth factor receptor mutation in lung cancer: Translational research at its best
Leal, T. A. B., & Ramalingam, S. S. (2024) · Cancer · doi:10.1002/cncr.35353 · Cited by 3
EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer
Saw, S. P. L., Takano, A. M., Zhou, S., Hlaing, N. O., James, A., Joseph, C. R., Lai, G. G. Y., Lim, W., Kanesvaran, R., Ang, M., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108463 · Cited by 2
Prognostic stratification through smoking status and cumulative smoking dose in advanced non-small cell lung cancer immunotherapy: a dose-dependent real-world analysis
Yang, L., Wang, H., Tian, P., & Li, W. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1590825 · Cited by 2
Targeting ILT4 to Improve Immunotherapy Efficacy in Solid Tumour: From Bench to Bedside
Gao, A., Wang, S., & Sun, Y. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s548082 · Cited by 2
Bibliometric analysis of research trends and hotspots in immunotherapy biomarkers for non-small cell lung cancer from 2015 to 2024
Meng, X., Lu, Z., & Mi, F. (2026) · Discover Oncology · doi:10.1007/s12672-026-04436-z · Cited by 2
Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Comprehensive Review
Delasos, L., & Hassan, K. A. (2026) · JCO Oncology Practice · doi:10.1200/op-25-01061 · Cited by 2
Immunotherapy for patients with EGFR-TKI-resistant non-small-cell lung cancer: Potential mechanisms, efficacy predictors, and therapeutic integration
Wu, X., Shi, Y., Wang, D., Liu, B., Zhang, Y., Zhang, L., Qian, F., & Zhang, W. (2026) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2026.02.005 · Cited by 2
Immunotherapy for TKI-resistant, EGFR L858R-mutated non-small cell lung cancer: a systematic review and meta-analysis of randomized and single-arm studies
Zhang, P., Zhao, W., Ma, J., Li, Y., Peng, H., & Jiang, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1787310 · Cited by 2
Carboplatin, nab-paclitaxel plus atezolizumab in IMpower 130 trial: new weapons beyond controversies
Giglio, A. D., Nuvola, G., & Dall’Olio, F. G. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.12.69 · Cited by 2
Extremely high infiltration of CD8+PD-L1+ cells detected in a stage III non-small cell lung cancer patient exhibiting hyperprogression during anti-PD-L1 immunotherapy after chemoradiation: A case report
Wu, C., Zhou, K., Zheng, Y., Lv, D., Zhao, M., Hu, Y., Qi, F., Wang, X., & Feng, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.969493 · Cited by 2
Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer
Uehara, Y., & Hakozaki, T. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-872 · Cited by 2
Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers
Mohanty, S. K., Mishra, S. K., Amin, M. B., Agaimy, A., & Fuchs, F. S. (2023) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000395 · Cited by 3
[Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].
Liu, Y., & Miao, J. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.106.26 · Cited by 2
Sinus metastasis of lung adenocarcinoma: a case report
Xu, M., Sun, Q., Lv, X., Chen, F., Su, S., & Wang, L. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1323222 · Cited by 3
Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study
Jiang, K., Wu, L., Zheng, X., Xu, Y., Miao, Q., Zheng, X., Zhang, L., Huang, C., & Lin, G. (2024) · BMC Pulmonary Medicine · doi:10.1186/s12890-024-02905-1 · Cited by 2
Expansion of tumor-infiltrating lymphocytes in non-small cell lung cancer: Clinical potential and efficacy in EGFR mutation subsets
Lee, H., Lee, M., Lim, C. L., Park, H. S., Song, I. H., Jeong, B.-K., Kim, D. K., Kim, Y., Choi, S., Lee, G. D., et al. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110289 · Cited by 2
Real-world biomarker testing patterns: clinical-pathological portrait of early and late non-small cell lung cancer in hub and spoke North Italian centers
Tinè, M., Pezzuto, F., Orlandi, M., Caliò, A., Marletta, S., Bondavalli, T., Giongo, D., Reghellin, D., Posenato, I., Santacatterina, M., et al. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-107 · Cited by 2
Prognostic Factors in Japanese EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study
Takashima, K., Wakabayashi, H., Murakami, Y., Saiki, A., & Matsuzawa, Y. (2024) · Drugs - Real World Outcomes · doi:10.1007/s40801-024-00449-8 · Cited by 2
Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoma with micropapillary or solid histological subtypes: a single-center, single-arm, phase 2 trial
Kim, J., Bang, Y. H., Park, S., Jung, H. A., Sun, J., Ahn, J. S., Ahn, M., Jeon, Y. J., Lee, J. H., Cho, J. H., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103282 · Cited by 2
Is an immune checkpoint inhibitor really a hopeless therapeutic choice for EGFR-mutant non-small cell lung cancer (NSCLC) patients?
Kunimasa, K., Nishino, K., & Kumagai, T. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.02.18 · Cited by 2
Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report
Tokuyasu, H., Horie, M., Ishikawa, S., Sakai, H., Miura, H., & Yamasaki, A. (2019) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2019.100976 · Cited by 2
Successful immune checkpoint inhibition in an EGFR-mutant lung cancer patient refractory to epidermal growth factor receptor tyrosine kinase inhibitor treatment
Hochmair, M. J., Weinlinger, C., & Prosch, H. (2020) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000876 · Cited by 2
Improving therapy for patients with epidermal growth factor receptor‐mutant lung cancer
Arbour, K. C., & Riely, G. J. (2018) · Cancer · doi:10.1002/cncr.31289 · Cited by 2
Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?
Çetin, B., Bilgetekin, İ., & Özet, A. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.07.008 · Cited by 2
[Advances of the Correlation between Driver Gene Status and Immunotherapy in Non-small Cell Lung Cancer].
Chen, J., Jiang, D., & Huang, F. (2019) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2019.04.06 · Cited by 2
Case Report: A Metabolic Complete Response to Upfront Osimertinib in a Smoker Non-Small Cell Lung Cancer Patient Harbouring EGFR G719A/V769M Complex Mutation
Simionato, F., Calvetti, L., Cosci, M., Scarparo, S., & Aprile, G. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s280933 · Cited by 2
Osimertinib and chemotherapy combination to treat brain metastasis flare and osimertinib resistance by EGFR C797S
Blaquier, J. B., & Recondo, G. (2022) · Journal of Chemotherapy · doi:10.1080/1120009x.2022.2067705 · Cited by 2
Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports
Manapov, F., Nieto, A. E., Käsmann, L., Taugner, J., Kenndoff, S., Flörsch, B., Guggenberger, J., Hofstetter, K., Kröninger, S., Lehmann, J., et al. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2179479 · Cited by 2
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non–Small-Cell Lung Cancer With Novel Driver Alterations
Brambilla, M., Beninato, T., Piemontese, A., Mazzeo, L., Pircher, C. C., Manglaviti, S., Ambrosini, P., Signorelli, D., Lorenzini, D., Prelaj, A., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.08.004 · Cited by 2
Traitement des cancers bronchiques non à petites cellules de stades avancés mutés EGFR : quels inhibiteurs ? Quelles séquences thérapeutiques ?
Cadranel, J. L., Fallet, V., Baldacci, S., & Cortot, A. B. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(20)30100-2 · Cited by 2
Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer
Majeed, H., & Amir, E. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.153 · Cited by 2
Role of immune checkpoint blockers in patients with EGFR mutation
Ward, J. P., & Morgensztern, D. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.09.13 · Cited by 2
Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?
Adderley, H., Ackermann, C. J., & Califano, R. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.116 · Cited by 2
Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Metro, G., & Maïo, M. D. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.07.12 · Cited by 2
Oncogenic pathways as the basis of primary immune ignorance
Patel, M. R. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170081 · Cited by 1
Vinorelbine in treatment of non-small cell lung cancer
Артамонова, Е. В. (2021) · Medical alphabet · doi:10.33667/2078-5631-2021-10-8-15 · Cited by 1
ROS1
Oesterich, L. G., & Riess, J. W. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_3 · Cited by 1
Nivolumab as maintenance therapy following platinum‐based chemotherapy in EGFR ‐mutant lung cancer patients after tyrosine kinase inhibitor failure: A single‐arm, open‐label, phase 2 trial
Kim, J., Choi, C., Ji, W., & Lee, J. C. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15083 · Cited by 1
Pulmonary Spindle Cell Carcinoma Mimicking Granulomatous Inflammation: A Rare Case Report and Brief Review of the Literature
Liu, Q., Zhang, J., Wei, M., Zhou, X., Sun, H., Dong, Y., & Zhang, D. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s480969 · Cited by 1
Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer—a case series of divergent results from a large reference laboratory
Strickland, K. C., Nesline, M., Previs, R. A., Ko, H. C., Cooper, M. A., Rushton, J. R., Wallen, Z. D., Pabla, S., Conroy, J. M., Sausen, M., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1445668 · Cited by 1
Overview of Systematic Reviews of ICIs in NSCLC With EGFR, ALK, ROS1, and RET Actionable Driver Mutations
Najeeb, S., Abdelrazeq, S. Y., Kelly, S., Wang, X., Skidmore, B., Nahar, N., Brouwers, M. C., & Wells, G. A. (2024) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2024.1025 · Cited by 1
Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
Lee, C. K., Liao, B.-C., Subramaniam, S., Chiu, C., Mersiades, A. J., Ho, C., Brown, C. S. B., Lai, C., Hughes, B. G. M., Yang, T., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100771 · Cited by 1
Self-citation
Global research trends of tumor microenvironment in non-small cell lung cancer with epidermal growth factor receptor mutation: a bibliometric analysis from 2014 to 2023
Chang, X., Wang, C., Wang, F., & Zhang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1555216 · Cited by 1
Traitement standard des cancers bronchiques non à petites cellules métastatiques mutés EGFR en première ligne et à progression
Lefèvre, A., & Besse, B. (2025) · Bulletin du Cancer · doi:10.1016/s0007-4551(25)00160-2 · Cited by 1
Neoadjuvant Immunochemotherapy for Stage II-IIIB Non-Small Cell Lung Cancer With Mutations Beyond EGFR 19del, L858R, and ALK Rearrangement
Ding, H., Tao, B., Xu, L., Jiang, G., & Wang, H. (2025) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2025.04.016 · Cited by 1
First-line immunotherapy in advanced non-squamous non-small cell lung cancer patients with rare mutations: a retrospective cohort study
Cao, W., Kou, F., Hu, W., Hu, L., Nie, J., Dai, L., Zhang, J., Rui, J., Knetki‐Wróblewska, M., Antonoff, M. B., et al. (2025) · Translational Lung Cancer Research · doi:10.21037/tlcr-2025-716 · Cited by 1
Real-World Comparative Study of Atezolizumab-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer
Ohiwa, A., Nishimura, T., Sakaguchi, T., Fujimoto, H., Kodama, S., Fujiwara, A., Nakahara, H., Isobe, T., Hirai, T., Yagi, A., et al. (2025) · Cancers · doi:10.3390/cancers17223630 · Cited by 1
Efficacy and safety comparisons of PD-1 versus PD-L1 inhibitors in patients with solid cancer: a systematic review and meta-analysis
Yu, J., Zhou, Q., Wang, G., Shi, S., Wang, H., Yang, J., Sun, X., Li, J., Shi, Y., Wang, J., et al. (2026) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2026.01.004 · Cited by 1
Self-citation
Multiomics Biomarkers for Differential Diagnosis of Pleural Effusion: Integration of Proteomic Markers and Single‐Cell Transcriptomics
Zhang, Z., Zhan, S., Tang, Y., Ling, Z., Wu, J., Rui, D., Wei, X., & Ming, M. (2026) · Human Mutation · doi:10.1155/humu/5946608 · Cited by 1
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China
Zhang, C., Jiang, B., Yan, L.-X., Peng, L., Li, J.-H., Chen, Z.-Y., Sun, Y.-X., su, J., Liao, R.-Q., Dong, S., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103994 · Cited by 1
Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance
Niu, J., Jing, W., Liu, Z., Si, Y., & 刘寨东 (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1845547 · Cited by 1
Case Report: Successful conversion surgery following chemo-antiangiogenic therapy in a lung adenocarcinoma patient with active rheumatoid arthritis and rare EGFR mutation after immunotherapy-triggered flare
Ma, J., Yan, P., Liu, C., & Wang, Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1795914 · Cited by 1
Research progress in immune checkpoint inhibitors in the treatment of oncogene-driven advanced non-small cell lung cancer.
Li, Y., Zhang, L., & Chen, J. (2020) · PubMed · doi:10.11817/j.issn.1672-7347.2020.190054 · Cited by 1
PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
Addeo, A., & Banna, G. L. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.07.10 · Cited by 1
[Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review].
Chen, R., Jiang, C., Ma, L., & Zhang, S. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.101.37 · Cited by 1

Authors: Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H.
Affiliations: The University of Sydney (AU)
St George Hospital (AU)
Chinese University of Hong Kong (HK)
National Taiwan University (TW)
Corresponding author: Lee, Chee Khoon
ORCID: Lee, Chee Khoon
Man, Johnathan
Links, Matthew
Gebski, Val
Mok, Tony
Yang, James Chih-Hsin
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2017-02
Volume: 12
Issue: 2
Pages: 403-407
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1016/j.jtho.2016.10.007
OpenAlex: W2538232731
Cited by: 839
References: 15
Citations by year: 2026: 47 · 2025: 61 · 2024: 68 · 2023: 84 · 2022: 93 · 2021: 98 · 2020: 100 · 2019: 100 · 2018: 123 · 2017: 62
FWCI: 85.21
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 365 d)
Locations: Journal of Thoracic Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: immune checkpoint inhibitors, EGFR-mutant non-small cell lung cancer, second-line therapy, nivolumab, pembrolizumab, atezolizumab, docetaxel, overall survival, advanced non-small cell lung cancer
MeSH terms: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Immunotherapy, Lung Neoplasms, Mutation, Prognosis, Randomized Controlled Trials as Topic, Cell Cycle Checkpoints, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks